Blood markers may spot Kids' lung disease earlier

NCT ID NCT07559435

Not yet recruiting Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to healthy controls. The goal is to improve early detection and treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to help doctors diagnose and predict the course of lung disease in children.
What could go wrong: This is a small, early-stage study with only 60 participants, so results may not apply to all children. The biomarkers may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blau syndrome interstitial lung disease interstitial lung disease specific to childhood juvenile dermatomyositis juvenile idiopathic arthritis mixed connective tissue disease systemic lupus erythematosus systemic sclerosis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC IMMUNE MEDIATED INTERSTITIAL LUNG DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.